Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.
Hum Immunol. 2013 Jul;74(7):842-8. doi: 10.1016/j.humimm.2013.04.002. Epub 2013 Apr 18.
The binding motif of human CTLA-4 is well known to be MYPPPY and for porcine CTLA-4 the binding motif is LYPPPY. Is this single amino acid difference of methionine (M) versus leucine (L) critical for the CTLA-4 binding? Recently, we have reported that the recombinant soluble porcine CTLA-4 was incapable of binding to human CD80. In this study we mutated L to M in the binding motif of the soluble porcine CTLA-4 and mutated M to L in the binding motif of the soluble human CTLA-4. We then analyzed how these mutations affected the binding affinity of the mutants to both porcine and human CD80(+) cells. The soluble porcine CTLA-4-L97M mutant partially lost its binding affinity to porcine CD80 compared to the wild-type and conferred very weak binding ability to human CD80. These results indicate that the L in the binding motif of porcine CTLA-4 is important for determining its binding ability to porcine CD80. Wild-type soluble human CTLA-4 binds to both human and porcine CD80 with comparable affinity, however, the soluble human CTLA-4-M97L mutant almost lost its binding ability to human CD80 and increased its binding ability to porcine CD80. These results indicate that M in the human CTLA-4 binding motif is extremely critical for its binding to human CD80. Those data suggest that the human CTLA-4 based recombinant protein drugs such as human CTLA-4-Ig can be used and/or tested in a porcine model. Conversely, the use of porcine CTLA-4 based recombinant protein drugs such as porcine CTLA-4-Ig is restricted to swine models. The difference in binding specificity of CTLA-4 observed in this study may be useful for studies such as pig to nonhuman primate xeno-transplantation. Porcine CTLA-4- and human CTLA-4-M97L mutant-based recombinant protein drugs can be used to specifically block the direct presentation by donor antigen presenting cells in pig to nonhuman primate xeno-transplantation. Human CTLA-4-M97L mutant-based recombinant protein drugs will be more ideal as it is without immunogenicity to human being.
人类 CTLA-4 的结合基序众所周知是 MYPPPY,而猪 CTLA-4 的结合基序是 LYPPPY。这种由甲硫氨酸(M)到亮氨酸(L)的单一氨基酸差异对 CTLA-4 的结合是否至关重要?最近,我们报道了重组可溶性猪 CTLA-4 不能与人 CD80 结合。在这项研究中,我们在可溶性猪 CTLA-4 的结合基序中突变 L 为 M,在可溶性人 CTLA-4 的结合基序中突变 M 为 L。然后,我们分析了这些突变如何影响突变体与猪和人 CD80(+)细胞的结合亲和力。与野生型相比,可溶性猪 CTLA-4-L97M 突变体部分丧失了与猪 CD80 的结合亲和力,并赋予了与人 CD80 非常弱的结合能力。这些结果表明,猪 CTLA-4 结合基序中的 L 对于确定其与猪 CD80 的结合能力很重要。野生型可溶性人 CTLA-4 与人 CD80 和猪 CD80 的结合亲和力相当,然而,可溶性人 CTLA-4-M97L 突变体几乎丧失了与人 CD80 的结合能力,而增加了与猪 CD80 的结合能力。这些结果表明,人 CTLA-4 结合基序中的 M 对于其与人 CD80 的结合至关重要。这些数据表明,基于人 CTLA-4 的重组蛋白药物,如人 CTLA-4-Ig,可以在猪模型中使用和/或测试。相反,基于猪 CTLA-4 的重组蛋白药物,如猪 CTLA-4-Ig,仅限于猪模型。在这项研究中观察到的 CTLA-4 结合特异性的差异可能对猪到非人类灵长类动物异种移植等研究有用。基于猪 CTLA-4 和人 CTLA-4-M97L 突变体的重组蛋白药物可用于特异性阻断供体抗原呈递细胞在猪到非人类灵长类动物异种移植中的直接呈递。基于人 CTLA-4-M97L 突变体的重组蛋白药物将更加理想,因为它对人类没有免疫原性。